HIGHLIGHTS
- who: Takeshi Osonoi and collaborators from the Tohoku University, Japan have published the paper: Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study, in the Journal: (JOURNAL) of April/30,/2023
- future: Studies are needed for the development of cardiovascular disease which requires long-term observation periods in large clinical studies.
SUMMARY
The XOR inhibitor febuxostat and the uricosuric drug benzbromarone inhibit ABCG2-mediated urate transport . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.